Media headlines about Oncolytics Biotech (NASDAQ:ONCY) have trended somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Oncolytics Biotech earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.4024953670619 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of Oncolytics Biotech (NASDAQ ONCY) remained flat at $0.33 during trading on Monday. The firm’s 50 day moving average price is $0.34 and its 200 day moving average price is $0.50. Oncolytics Biotech has a 52 week low of $0.24 and a 52 week high of $1.40.
About Oncolytics Biotech
Oncolytics Biotech Inc is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company’s clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials.
Receive News & Ratings for Oncolytics Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.